PMID- 28816832
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20220318
IS  - 1537-162X (Electronic)
IS  - 0362-5664 (Linking)
VI  - 40
IP  - 5
DP  - 2017 Sep/Oct
TI  - Reversible Splenial Lesion Syndrome After Intravenous Immunoglobulin Treatment 
      for Guillain-Barre Syndrome.
PG  - 224-225
LID - 10.1097/WNF.0000000000000236 [doi]
AB  - Reversible corpus callosum splenial (CCS) lesions have been described in patients 
      with varied etiologies. The most common causes of previously reported reversible 
      focal lesions of the CCS are viral encephalitis, antiepileptic drug 
      toxicity/withdrawal, and metabolic disorders. Intravenous immunoglobulin (IVIG) 
      therapy is used for different immune-mediated diseases. It is generally safe, and 
      serious adverse reactions are uncommon. We presented a rare case of disturbed 
      consciousness with reversible CCS lesions after IVIG therapy for Guillain-Barre 
      syndrome in an adult woman. In this case, we believe that IVIG therapy caused 
      reversible CCS lesions with encephalopathy and probably result of cytotoxic edema 
      and/or cerebral arterial vasospasm.
FAU - Uygur Kucukseymen, Elif
AU  - Uygur Kucukseymen E
AD  - Department of Neurology, Antalya Education and Research Hospital, Antalya, 
      Turkey.
FAU - Yuksel, Burcu
AU  - Yuksel B
FAU - Genc, Fatma
AU  - Genc F
FAU - Ozaydin Goksu, Eylem
AU  - Ozaydin Goksu E
FAU - Yildiz, Sevim
AU  - Yildiz S
FAU - Bicer Gomceli, Yasemin
AU  - Bicer Gomceli Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Corpus Callosum/diagnostic imaging/*pathology
MH  - Female
MH  - Guillain-Barre Syndrome/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects
MH  - Middle Aged
MH  - Syndrome
EDAT- 2017/08/18 06:00
MHDA- 2018/05/22 06:00
CRDT- 2017/08/18 06:00
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/08/18 06:00 [entrez]
AID - 10.1097/WNF.0000000000000236 [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2017 Sep/Oct;40(5):224-225. doi: 
      10.1097/WNF.0000000000000236.